Three hospitalized, 21 injured after bee attack in France
July 7 (UPI) -- Three people were hospitalized and 21 more were injured after being attacked by a swarm of bees in the French town of Aurillac, authorities said.
This occurred at around 10 a.m. local time on Sunday as passers-by were stung over the span of 30 minutes in the town.
According to the mayor and the prefecture, the bees came from hives nearby on the roof of the town's large Bordeaux hotel.
Emergency services treated the three victims before being admitted to the hospital after allergic reactions to being sung. One elder suffered a cardiac arrest but he was able to be resuscitated.
According to the fire brigade, the victims' conditions have been stabilized by Sunday afternoon.
The mayor of Aurillac, Pierre Mathonier, believed that this incident was linked to the invasion of Asian hornets in Europe, which potentially causes honey bees to be aggressive.
"It raises questions about the presence of hives in the city center," said Mathonier as he had "never experienced such behavior" from the hotel bees.
After this incident, the mayor said he was considering banning beehives in his municipality.
According to the National Institute for Health and Clinical Excellence, there are between two to nine deaths from bee or wasp stings in the U.K. every year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
42 minutes ago
- Newsweek
Americans Advised To Avoid the Sun in 16 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Americans in at least 16 states could see heightened levels of ultraviolet (UV) radiation on Friday, according to a forecast published by the Environmental Protection Agency (EPA). Why It Matters The EPA cautions that elevated UV radiation levels can increase the risk of skin burns, eye damage and long-term health problems such as skin cancer. What To Know The UV index ranges from 1 to 11. The levels, and their corresponding advice, are: 1-2: Low (minimal risk from UV rays for the average person) Wear sunglasses on bright days. In winter, snow can reflect UV rays and nearly double exposure. Use SPF 15+ sunscreen if you burn easily. 3-5: Moderate (moderate risk of harm from unprotected sun exposure) Cover up, wear a hat and sunglasses. Use SPF 15+ sunscreen. Stay in the shade near midday when the sun is strongest. 6-7: High (high risk of harm from unprotected sun exposure) Seek shade during the midday hours. Wear protective clothing, sunglasses, and SPF 15+ sunscreen. 8-10: Very High (very high risk of harm; sun protection is essential) Take extra precautions, including wide-brimmed hats and long sleeves. Minimize exposure between 10 a.m. and 4 p.m. Be aware: white sand and similar surfaces reflect UV rays and increase exposure. 11+: Extreme (extreme risk of harm) Try to avoid sun exposure from 10 a.m. to 4 p.m. Reapply SPF 30+ sunscreen every 2 hours. Seek shade, wear full coverage, and use sun protection. An EPA forecast map shows which areas could see the highest UV levels on Friday. An EPA forecast map shows which areas could see the highest UV levels on Friday. Environmental Protection Agency According to the EPA's UV index forecast for solar noon—when the sun is at its highest point in the sky—parts of the following states could see levels of at least 11 on Friday. California Nevada Utah Wyoming Arizona Colorado New Mexico Texas Oklahoma Louisiana Mississippi Alabama Georgia Florida North Carolina South Carolina What People Are Saying Antony Young, emeritus professor of experimental photobiology and dermatology at King's College, London, previously told Newsweek: "The UV index [UVI] is a measure of the sunburning power of higher the UVI, the shorter the time you need in the sun to burn." Richard Weller, a professor of medical dermatology at the University of Edinburgh, previously told Newsweek that sunlight can cause photoaging, the premature aging of the skin as a result of prolonged and repeated exposure to UV radiation. "Sunburn is a risk factor for melanoma skin cancer, which is the most serious of the skin cancers." What Happens Next Each day, the UV index forecast map is created using data provided by the National Weather Service, the EPA says.
Time Business News
an hour ago
- Time Business News
Breakthrough Innovations Transforming Lung Cancer Diagnosis and Treatment
Lung cancer is a type of cancer that begins in the lungs, often caused by smoking, exposure to pollutants, genetic factors or commercial threats. Lung cancer market is increasing due to growing global lung cancer rate, awareness and increase in screening programs, progress in clinical technologies (such as low -dosage CT scans and liquid biopsy) and increasing remedies and development of targeted remedies and immunotherapy. Additionally, better healthcare in aging population and emerging areas is promoting infrastructure and early detection and demand for effective treatment solutions. Key Growth Drivers and Opportunities Growing Global Lung Cancer Rate: Rising global lung cancer rate is a major driver of lung cancer market development, as it increases the demand for early identity, accurate diagnosis and effective treatment solutions. One of the major causes of cancer-related deaths worldwide with lung cancer, healthcare systems are making heavy investments in advanced screening tools such as low-dosage CT scans and biomarker-based diagnosis to enable the first diagnosis. At the same time, rising patient numbers are accelerating the development and adoption of innovative remedies including targeted drugs and immunotherapy. The burden of growing disease also attracts more research funds and industry investment, further fuel to market expansion. Challenges The lung cancer market faces several borders, including advanced diagnosis and high cost of targeted treatments, which can limit access to areas with especially low and moderate income. Delayed diagnosis also disrupts the results of treatment due to lack of awareness, limited screening programs and non-specific initial symptoms. Additionally, the challenge of complex regulatory routes, delayed stage patients, and the challenge of managing side effects from therapy disrupts the market growth despite technological progress. Innovation and Expansion EQUAL Study Launches High-Risk Group Lung Cancer Screening Trial In May 2025, Researchers at the Dana-Farber Cancer Institute have begun testing a new, in-house blood test in an effort to screen for lung cancer and identify those who are at a higher risk of developing the disease even if they have never used tobacco. Epidermal growth factor receptor (EGFR) gene mutations can be common in the Asian and Hispanic/Latinx populations, which is the subject of the EQUAL (EGFR ctDNA Quantitative Assessment for Lung Cancer screening in Asian and Latinx populations) study. Possessing this mutation increases the risk of lung cancer because EGFR type mutations are linked to the illness. Additionally, the number of cancer diagnoses among Asian or Hispanic/Latinx individuals is increasing at a faster rate. With India's First LungLife Screening Program to Fight Lung Cancer, Apollo Cancer Centre Sets the Standard In March 2025, India's first LungLife Screening Program for early lung cancer diagnosis has been introduced by Apollo Cancer Centres (ACCs), a pioneer in state-of-the-art cancer care. Lung cancer, which makes up 5.9% of all malignancies and 8.1% of cancer-related deaths in India, is the target of this ground-breaking project. Early identification increases the survival rate and improves treatment results (LINK). Low-dose computed tomography (LDCT) early screening can greatly increase survival chances and help with early diagnosis. However, almost 80% of high-risk patients have never spoken to their doctors about screening. To allow early detection and save lives, it is imperative to improve knowledge and communication regarding lung cancer screening, particularly among high-risk individuals. Inventive Sparks, Expanding Markets The key players operating the lung cancer market include AstraZeneca, Hoffman La Roche, Eli Lilly and Company, Pfizer Inc., Merck & Co., Amgen Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb Company. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
UPI
2 hours ago
- UPI
African psychedelic might help combat vets recover from brain injury
The drug ibogaine, derived from the roots of an African shrub called iboga, can safely and effectively treat long-term symptoms of traumatic brain injury in veterans, according to findings from a study of 30 vets published in the journal Nature Mental Health. July 25 (UPI) -- Veterans who receive traumatic brain injuries in combat often experience crippling post-traumatic stress disorder, anxiety and depression, leaving them hopeless and potentially suicidal. But help might be on the way from an unlikely source -- a psychedelic drug called ibogaine. The drug, derived from the roots of an African shrub called iboga, can safely and effectively treat long-term symptoms of traumatic brain injury in veterans, according to findings from a study of 30 vets recently published in the journal Nature Mental Health. The veterans crossed the border into Mexico to receive treatment with ibogaine, which is outlawed in the U.S., researchers said. "Before the treatment, I was living life in a blizzard with zero visibility and a cold, hopeless, listless feeling," study participant Sean, a 51-year-old veteran from Arizona with six combat deployments, said in a news release. "After ibogaine, the storm lifted." Scans reveal that ibogaine alters brain activity in ways that can lower stress and help veterans better process their trauma, researchers found. "No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury," senior researcher Dr. Nolan Williams, an associate professor of psychiatry and behavioral sciences at Stanford Medicine in Palo Alto, Calif., said in a news release. "The results are dramatic, and we intend to study this compound further." People who take ibogaine often report the experience as a "waking dream," in which they reflect upon memories and witness intense hallucinations, according to the University of California-Berkeley Center for the Science of Psychedelics. The compound is used in African religious ceremonies, and has been studied as a potential antidepressant and aid to shake drug addiction, the UC-Berkeley Center says. Ibogaine has been designated a Schedule 1 controlled substance since 1970 in the United States, preventing its medical use. However, clinics in both Canada and Mexico offer legal ibogaine treatments, researchers noted. For this research, researchers worked with a small group of 30 special operation veterans who had long-term symptoms from traumatic brain injuries and repeated exposure to blasts. "There were a handful of veterans who had gone to this clinic in Mexico and were reporting anecdotally that they had great improvements in all kinds of areas of their lives after taking ibogaine," Williams said. "Our goal was to characterize those improvements with structured clinical and neurobiological assessments." Independently, the veterans signed up for ibogaine treatment at a Mexican clinic run by Ambio Life Sciences, researchers said. They were assisted by VETS Inc., a foundation that helps facilitate psychedelic-assisted therapies for veterans. The clinic provided oral ibogaine under medical monitoring, along with a dose of magnesium to help prevent heart complications that have been associated with the drug, researchers said. "These men were incredibly intelligent, high-performing individuals who experienced life-altering functional disability from TBI during their time in combat," Williams said. "They were all willing to try most anything that they thought might help them get their lives back." Stanford doctors assessed the veterans prior to their sojourn in Mexico and gave them a follow-up exam once they'd returned to the States. Among the 30 veterans, 23 met the criteria for PTSD, 14 for anxiety disorder and 15 for alcoholism, researchers said. About 19 of the participants had been suicidal at some point, and seven had attempted suicide. Within one month of ibogaine treatment, the vets experienced an average 88% reduction in PTSD symptoms, 87% in depression symptoms and 81% in anxiety symptoms, researchers report. They also experienced reduced disability and improvements in their concentration, information processing, memory and impulsivity, results show. "I wasn't willing to admit I was dealing with any TBI challenges. I just thought I'd had my bell rung a few times - until the day I forgot my wife's name," Craig, a 52-year-old study participant from Colorado who served 27 years in the U.S. Navy, said in a news release. "Since [ibogaine treatment], my cognitive function has been fully restored," Craig continued. "This has resulted in advancement at work and vastly improved my ability to talk to my children and wife." EEG and MRI brain scans reveal why the drug might help veterans, researchers said. Veterans whose ability to plan and organize improved after ibogaine treatment tended to show an increase in brain waves called theta rhythms, results show. Stronger theta rhythms might encourage neuroplasticity and cognitive flexibility. Likewise, those with reduced PTSD symptoms tended to display less complex brain activity in the cortex - a sign that the drug helps lower the heightened stress response associated with the disorder. These sorts of brain scans might help doctors identify patients who could most benefit from ibogaine, researchers said. There were no serious side effects from ibogaine, and no instances of heart problems, researchers said. During treatment, the veterans reported typical symptoms like headache and nausea. Based in part on these findings, Texas recently approved a $50 million initiative to fund clinical trials of ibogaine. The program will provide matching state funds for private investments in ibogaine trials that might lead to U.S. Food and Drug Administration approval, researchers said. "In addition to treating TBI, I think this may emerge as a broader neuro-rehab drug," Williams said. "I think it targets a unique set of brain mechanisms and can help us better understand how to treat other forms of PTSD, anxiety and depression that aren't necessarily linked to TBI." The study did not receive any funding from Ambio Life Sciences or VETS Inc., researchers noted. More information The University of California-Berkeley Center for the Science of Psychedelics has more on ibogaine. Copyright © 2025 HealthDay. All rights reserved.
